Nothing Special   »   [go: up one dir, main page]

Wu et al., 2015 - Google Patents

Weak protein interactions and pH-and temperature-dependent aggregation of human Fc1

Wu et al., 2015

View PDF @Full View
Document ID
454311241277158506
Author
Wu H
Truncali K
Ritchie J
Kroe-Barrett R
Singh S
Robinson A
Roberts C
Publication year
Publication venue
MAbs

External Links

Snippet

The Fc (fragment crystallizable) is a common structural region in immunoglobulin gamma (IgG) proteins, IgG-based multi-specific platforms, and Fc-fusion platform technologies. Changes in conformational stability, protein-protein interactions, and aggregation of NS0 …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8665—Signal analysis for calibrating the measuring apparatus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infra-red light

Similar Documents

Publication Publication Date Title
Wu et al. Weak protein interactions and pH-and temperature-dependent aggregation of human Fc1
Bandyopadhyay et al. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197
Arora et al. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody
Xu et al. Structure, heterogeneity and developability assessment of therapeutic antibodies
Arora et al. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity
Seo et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
Zheng et al. The impact of glycosylation on monoclonal antibody conformation and stability
Wang et al. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion
Ghosh et al. Relating protein–protein interactions and aggregation rates from low to high concentrations
Nichols et al. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions
Nupur et al. Assessment of structural and functional similarity of biosimilar products: rituximab as a case study
Wang et al. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment
Correia Stability of IgG isotypes in serum
Rathore Follow-on protein products: scientific issues, developments and challenges
Jones et al. Complementary MS methods assist conformational characterization of antibodies with altered S–S bonding networks
Mach et al. Electrostatic interactions of monoclonal antibodies with subcutaneous tissue
Magnenat et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
Spencer et al. Solubility evaluation of murine hybridoma antibodies
Alsenaidy et al. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles
Plath et al. Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs
Lu et al. Characterization of monoclonal antibody size variants containing extra light chains
Ponniah et al. Characterization of the acidic species of a monoclonal antibody using weak cation exchange chromatography and LC-MS
Chakrabarti et al. Studies to prevent degradation of recombinant Fc-fusion protein expressed in mammalian cell line and protein characterization
Rouby et al. Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry
Zhang et al. Structural changes and aggregation mechanisms of two different dimers of an IgG2 monoclonal antibody